EFFECT OF DUAL PPAR α/γ AGONIST SAROGLITAZAR ON LIPID PROFILE AND LIVER ENZYMES IN NAFLD PATIENTS

Abstract

Background: The metabolic syndrome demonstrates as nonalcoholic fatty liver disease (NAFLD), which is characterized by hepatic fat accumulation linked to varying degrees of inflammation and fibrosis. The NAFLD constitutes a broad category of chronic liver disease, encompassing nonalcoholic fatty liver, nonalcoholic steatohepatitis, and cirrhosis.